Guide Executive Team with meaningful and insightful financial analysis related to business operations, new growth opportunities and existing performance trends against operating plans. Functions as the analytical engine of the company, uncovering valuable insights and providing well-rounded analyses that drive optimal strategic decisions. Key Accomplishments:• Wave Swell Award recipient in recognition of significant contributions that have enabled senior management to make critical business decisions• Spearheaded a cross-functional Workforce Planning initiative that ultimately resulted in the 5 Pillars of Operational Excellence• Drove the prioritization of Wave’s portfolio and aligned corporate strategy and priorities• Operationalized the contractual obligations of the Wave-Takeda strategic collaboration to ensure compliance and facilitate successful execution• Maintain Wave’s “corporate model” to quantify various investment scenarios to proactively compute cash runway, identify value inflections points, and assess future financing needs• Manage cost-sharing arrangement between Wave US and UK through portfolio valuation that influence RAB share calculations • Directed the development and maintenance of a Molecule’s development lifecycle template in order to facilitate the addition of assets in long range plan• Optimize partnership with Program Team leadership; ensure financial projections are an accurate representation of clinical development and program activities• Analyze Wave’s financial projections against sell-side analyst reports within investor community, report significant deviations to Executive Team, and influence external messaging decisions• Drove operational improvements and efficiency by leading and completing the revamp of the Chart of Accounts and Purchase Categories; the revision of the Delegation of Authority policy; and the refresh of finance, legal, and procurement approval flow and internal control policies

Key Accomplishments:• Established the Quarterly Business Review process that proactively informs Executive Management of the financial state of the company, its trajectory in meeting goals, and that highlights key business activities that are affecting company performance• Designed an effective report tool that facilitated monitoring for and provided early insight on deviations from plan, allowing the ability to take appropriate corrective action• Developed an operative Gross to Net model to automate the calculation of sales reserves, including Marketing Co-Pay and Voucher programs, Commercial and Medicare Part D contract rebates, Medicaid, commercial chargebacks, fees, and returns• Collaborated with Accounting and Manufacturing teams to produce a reliable Cost of Goods forecast, considering the complex and variable API pricing structures across multiple CDMOs • Evaluated and performed valuation analysis on employing a CDMO model versus owning a manufacturing facility• Challenged API capacity expansion plan through the analysis of API MT needs versus product Demand forecast• Completed a 7-year Long Range Plan that reflects our company’s value drivers for potential investors, and enables Keryx to focus on what's critical to the business in a dynamic environment

• Awarded two Cube Awards, in 2012 and 2013, in recognition of innovative game-changing contributions and superior performance, resulting in promotion to Senior Manager, FP&A Operations• Successfully led three corporate-wide workforce planning and budgeting cycles, including complex integration of acquired companies and the global expansion to Zurich, Switzerland• Supported US and Global administrative and commercial operations through the delivery of monthly financial performance report package, provision of finance and accounting guidance, frequent communication, and strong business partnership• Led a team of five Senior FP&A Managers, as well as manage two direct reports, through annual Cubist planning cycles including workforce planning, long range planning, budgeting and forecasting • Performed Executive-level analysis and presentation of Cubist overall P&L performance as it compares to company issued Guidance to investors, as well as Analyst consensus• Managed and analyzed corporate financials against GAAP and Non-GAAP investor guidance• Developed The Cubist Epoch, a quarterly financial performance retrospective package, leveraged by Executive Management during Earnings Release and to review company revenue and operational performance trends

• Engineered and implemented a multifaceted Gross to Net Sales financial model that automatically calculates contra-revenue liability reductions to Feraheme™ gross sales to determine net sales for a given period• In 2009, delivered 6-figure savings to Net Sales through diligent evaluation and analysis of actual Feraheme™ sales and market demand data and further refinement of assumptions used in the Gross to Net Sales financial model• Collaborate regularly with Sr. Manager of Pricing and Customer Contracts to analyze volume/market share rebate and discount programs associated with customer contracts of different classes of trade. Jointly examined chargeback and customer market share information to determine appropriate rebate liability to be accrued by Finance at period end • Led the development of annual and mid-year Commercial Operations plan and latest estimates• Enabled departmental directors to effectively track and remain within a 5% proximity of a multi-million dollar Commercial Operations budget through accurate and timely financial projections and analyses • Guided executive management in making strategic business decisions through the development and presentation of a 5-year pro forma profit and loss statement and net present value assessment• Organized best practice initiatives and facilitated process improvement to enhance Accounts Payable functions, reducing monthly processing time by 20%

• Co-developed a Gross to Net sales model that estimated reserves upon considering contra-revenue liabilities such as rebates and discounts, and liabilities involving Wholesalers, Medicaid and Managed Care Organizations, and marketing programs such as the Tyzeka™ Voucher and Patient Savings Card program and Money-back Guarantee• Designed a robust financial model to enhance the tracking process of the shared budget and marketing expense of the Idenix-Novartis partnership, encouraging a more disciplined and unified planning and forecasting process• Assisted in the development of Executive and Board level plan and sales forecast presentations• Supervised open marketing projects to track scope of work, schedule of expenses, and to ensure accuracy of accruals for month end, quarter end, and year-end financial reporting

• Promoted to manage and lead the Corporate Advantage Financial Incentive program, the signature discount program of Boston Scientific Corporate Sales• Diligently administered GPO contracts (Health Trust Purchasing Group and Novation) and IDN (Health Management Associate, Bon Secours, West Penn, and HCA Divisions)• Developed and completed relevant metrics for contract analysis used as guidance by Directors of Sales in determining how best to manage GPO and IDN accounts under their management